Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hee Jung Shin is active.

Publication


Featured researches published by Hee Jung Shin.


Therapeutic Drug Monitoring | 2015

Functional Study of Haplotypes in UGT1A1 Promoter to Find a Novel Genetic Variant Leading to Reduced Gene Expression.

Hee Jung Shin; Jason Yongha Kim; Hyun Sub Cheong; Han Sung Na; Hyoung Doo Shin; Myeon Woo Chung

Background: Uridine diphosphate glucuronyltransferase 1 family, A1 (UGT1A1) encodes for an enzyme that is a part of glucuronidation pathway, and a number of studies have shown that the promoter polymorphisms of UGT1A1 are associated with various diseases and drug response. In this study, we examined a possible association between UGT1A1 promoter haplotypes and the gene expression level. Methods: To identify promoter haplotype structure population, we directly sequenced the promoter region of UGT1A1 in 192 healthy Korean to identify 10 UGT1A1 promoter single-nucleotide polymorphisms (SNPs). Then, we genotyped the 10 SNPs in additional 192 non-Korean samples comprised of Chinese, Japanese, European American, and African American, and constructed haplotype structures. Furthermore, we conducted luciferase assay for the promoter SNP haplotypes to examine a possible expression change. Results: rs3755319C—rs2003569A—rs887829C—rs8175347(TA)6 (6.60 ± 0.15) and rs3755319A—rs2003569 G—rs887829C–rs8175347(TA)7 (2.79 ± 0.97) led to significantly lower gene expression when compared with rs3755319C—rs2003569 G—rs887829T—rs8175347(TA)6 (8.28 ± 0.60). Conclusions: Our result suggests that the haplotypes in UGT1A1 promoter region can affect the expression level of the gene and drug metabolism associated with UGT1A1. Furthermore, in addition to rs8175347, rs3755319 was found to induce lower gene expression of UGT1A1.


Laboratory Animal Research | 2017

Comparison of commonly used ICR stocks and the characterization of Korl:ICR

Hye-Jun Shin; Young Min Cho; Hee Jung Shin; Hae Deun Kim; Kyung Min Choi; Mi Gyeong Kim; Hyoung Doo Shin; Myeon-Woo Chung

Mouse is a commonly used animal in life science studies and is classified as outbred if genetically diverse and inbred if genetically homogeneous. Outbred mouse stocks, are used in toxicology, oncology, infection and pharmacology research. The National Institute of Food and Drug Safety Evaluation (NIFDS; former the Korea National Institute of Health) have bred ICR mice for more than 50 years. We investigated to provide users with information and promote accountability to the Korl:ICR. To secure the indigenous data, biological characteristics of Korl:ICR were identified by comparing with other ICR stocks. This domestic ICR stock was denominated as ‘Korl:ICR’. Phylogenetic analysis using SNPs indicated that the population stratification of the Korl:ICR was allocated different area with other ICR. In addition, we measured litter size, body weight, body length, various organ weight, hematology and clinical blood chemistry of the Korl:ICR compared to other ICR. Otherwise, there are no significant differences among the biological phenotypes of Korl:ICR and other ICR. These results suggest that as a genetically indigenous source colony, the Korl:ICR is seperated (or independent) stock with other ICR. Also, we confirmed that there is no difference among the Korl:ICR and other ICR on biological phenotypes. Therefore, the Korl:ICR source colony might be a new stock in distinction from other ICR, it is a good milestone in securing ownership of the national laboratory animal resource. The NIFDS expects that the Korl:ICR mice will be useful animal resource for our domestic researchers.


Therapeutic Drug Monitoring | 2015

Determination of DPYD enzyme activity in Korean population.

Joong-Gon Shin; Tae Sun Kang; Hyun Sub Cheong; Hee Jung Shin; Hyun Joo Park; Han Sung Na; Hyoung Doo Shin; Myeon Woo Chung

Background: Dihydropyrimidine dehydrogenase (DPYD) is an enzyme that regulates the rate-limiting step in pyrimidine metabolism, especially catabolism of fluorouracil. This study was performed to analyze the association between DPYD genetic variants and DPYD enzyme activity in the Korean population. Methods: We screened the genetic variants and analyzed the enzyme activity in 73 healthy Korean subjects (69 men and 4 women; mean age, 22.6 years). Direct sequencing was conducted using the ABI 3730XL system, and enzyme activity was determined using high-performance liquid chromatography. Results: A total of 83 genetic variants were observed. Among the identified genetic variants, 32 were polymorphic including 3 core and 11 novel genetic variants. Association analysis between each genetic variant and enzyme activity in Korean subjects showed that 2 novel genetic variants, −832 G>A and −131 C>A, induced a significant difference in enzyme activity (P < 0.05). Conclusions: To our knowledge, this is the first study that has examined the association between enzyme activity and DPYD genetic variants in the Korean population. In this study, we identified novel genetic variants that are associated with the enzyme activity. These findings will be valuable for further pharmacogenetic studies and especially useful for personalized medicine.


Toxicological research | 2011

Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line

Hye Ja Lee; Mi Kyung Park; Young Ran Park; Donghak Kim; Chul-Ho Yun; Young-Jin Chun; Hee Jung Shin; Han Sung Na; Myeon Woo Chung; Chang Hoon Lee

The cytochrome P450 (P450, CYP) are the superfamily of heme-containing monooxygenase enzymes, found throughout all nature including mammals, plants, and microorganisms. Mammalian P450 enzymes are involved in oxidative metabolism of a wide range of endo- and exogenous chemicals. Especially P450s involved in drug metabolisms are important for drug efficacy and polymorphisms of P450s in individuals reflect differences of drug responses between people. To study the functional differences of CYP2A6, CYP2D6, and CYP4A11 variants, we cloned the four CYP2A6, three CYP2D6, and three CYP4A11 variants, which were found in Korean populations, in mammalian expression vector pcDNA by PCR and examined their expressions in COS-7 mammalian cells using immunoblots using P450 specific polyclonal antibodies. Three of four CYP2A6, two of three CYP4A11, and two of three CYP2D6 variants showed expressions in COS-7 cells but the relative levels of expressions are remarkably different in those of each variants. Our findings may help to study and explain the differences between functions of CYP variants and drug responses in Korean populations.


Scientific Reports | 2017

Genetic and phenotypic characterization of the novel mouse substrain C57BL/6N Korl with increased body weight

Kyungmin Choi; Jaehoon Jung; Young Min Cho; Kwondo Kim; Mi-Gyeong Kim; Jin-Ho Kim; Huibae Kim; Hee Jung Shin; Hae Deun Kim; Seung-Tae Chung; Seoae Cho; Myeon-Woo Chung

In inbred mouse lines, there is generally little genetic difference between individuals. This small genetic variability facilitates carrying out research on minute changes of various traits and the gene pool. Also, characterizing the diversity and detecting selective genetic and phenotypic signatures are crucial to understanding the genomic basis of a population and to identify specific patterns of evolutionary change. In this study, we investigated the underlying genetic profiles of a newly developed mouse strain, C57BL/6NKorl (Korl), established through sibling mating over 30 generations. To analyse the distinctive genomic features of Korl mice, we used whole-genome sequencing from six samples, which were compared to those of other C57BL/6N-based mouse strains. Korl strain-specific polymorphisms were identified and signatures of a selective sweep were detected. In particular, the candidate genes related to the increased body weight of the Korl strain were identified. Establishment of the genetic profile of Korl mice can provide insight into the inbreeding-induced changes to the gene pool, and help to establish this strain as a useful model for practical and targeted research purposes.


Genes & Genetic Systems | 2016

Expression efficiency of NAT2 haplotypes in a Korean population.

Han Sung Na; Jin Sol Lee; Hyun Sub Cheong; Hee Jung Shin; Tae Sun Kang; Hyun Joo Park; Hyoung Doo Shin; Myeon Woo Chung

Since NAT2 single-nucleotide polymorphisms (SNPs) are responsible for the efficacy of arylamines and hydrazine drugs, defining the effects of these SNPs in various ethnicities is an important factor in the development of personalized medicine. In the present study, we examined the expression efficiency of NAT2 using promoter haplotypes identified in a Korean population. To construct NAT2 promoter haplotypes, seven NAT2 promoter SNPs (rs4646241, rs4646242, rs4646243, rs4646267, rs4345600, rs4271002 and rs4646246) were genotyped in a total of 192 Korean subjects. A luciferase assay was performed using the three commonest haplotypes to evaluate enzyme expression level of NAT2 promoter haplotypes. The most common haplotype (TACGAGG) showed the lowest enzyme expression level (0.72 ± 0.06 relative light units (RLU)/[β-galactosidase]). The second (CGTAAGA) and third (TATAACA) commonest haplotypes showed intermediate and the highest enzyme expression level (0.99 ± 0.05 and 1.45 ± 0.11 RLU/[β-galactosidase]), respectively. Haplotype comparison among populations showed that Asian populations had a high proportion of the haplotype for lowest enzyme expression. Haplotype frequencies of Caucasian and African ethnicities were markedly different from those of Korean ethnicity. Results from the present study should contribute to the expansion of our current understanding of the pharmacogenetics field.


Biological & Pharmaceutical Bulletin | 2012

Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).

Songhee Han; Seunghye Choi; Young-Jin Chun; Chul-Ho Yun; Chang Hoon Lee; Hee Jung Shin; Han Sung Na; Myeon Woo Chung; Donghak Kim


Archives of Pharmacal Research | 2015

Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2 family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations

Jeong-Hyun Kim; Hyun Sub Cheong; Byung Lae Park; Lyoung Hyo Kim; Hee Jung Shin; Han Sung Na; Myeon Woo Chung; Hyoung Doo Shin


Biomedical Reports | 2014

Screening for 392 polymorphisms in 141 pharmacogenes

Jason Yongha Kim; Hyun Sub Cheong; Tae Joon Park; Hee Jung Shin; Doo Won Seo; Han Sung Na; Myeon Woo Chung; Hyoung Doo Shin


Genes & Genomics | 2015

Direct sequencing for comprehensive screening of LDLR genetic polymorphisms among five ethnic populations

Jeong-Hyun Kim; Hyun Sub Cheong; Lyoung Hyo Kim; Hee Jung Shin; Han Sung Na; Myeon Woo Chung; Hyoung Doo Shin

Collaboration


Dive into the Hee Jung Shin's collaboration.

Top Co-Authors

Avatar

Myeon Woo Chung

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Young Min Cho

Seoul National University

View shared research outputs
Top Co-Authors

Avatar

Han Sung Na

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar

Myeon-Woo Chung

Food and Drug Administration

View shared research outputs
Top Co-Authors

Avatar

Jin-Ho Kim

Seoul National University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chul-Ho Yun

Chonnam National University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge